ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type ...( Results presented at the 43rd Eur...),Health

Results presented at the 43rd European Association for the Study of

Diabetes Annual Meeting

AMSTERDAM, The Netherlands, Sept. 19 /PRNewswire/ -- Results presented today at the 43rd Annual Meeting of the European Association for the Study of Diabetes demonstrate the ability of ACTOS(R) (pioglitazone HCl) to reduce the risk of ischemic cardiovascular disease in patients with type 2 diabetes. ACTOS is an oral antidiabetic agent for type 2 diabetes belonging to the thiazolidinedione (TZD) class of drugs.

Study Design and Results (PS130 / Abstract #1257)

This retrospective analysis of case records from a large managed care database of patients with diabetes showed that therapeutic regimens that included ACTOS were associated with reductions in the risk for stroke or myocardial infarction (MI) compared to non-thiazolidinedione therapies. The adjusted relative risk of stroke for the ACTOS group was 20 percent lower than that for the group not receiving ACTOS. Likewise, the risk of sustaining a heart attack over the study period was 38 percent lower in the patients receiving ACTOS than in those taking an antidiabetes drug regimen that did not include ACTOS.

"In this study, ACTOS was associated with reduced risk of heart attack and stroke," said Robert Spanheimer, M.D., Takeda Pharmaceuticals North America, Inc., senior medical director of diabetes and metabolism. "These outcomes - in a real world setting - are consistent with findings of no increase in total macrovascular events or death from PROactive, a prospective, randomized, controlled outcomes study."

Case records from January 2003 through June 2006 from a large managed care database of diabetes patients who were at least 45 years of age:

-- had not had a stroke or MI for the last six months and who were taking

either ACTOS (11,433 patients) with or without any other antidiabetes

treatment (excluding rosiglitazone, another member
'/>"/>